ArticleAnti-cancer agents in medicinal chemistry2013

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.

Vita M Golubovskaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.